Registration of Patent of Technology to increase safety decided, leading to export of stem cell therapy

• Dr. Jeong-Chan Ra’s research results are recognized after his return to Biostar Stem Cell Research Institute
• International clinical trial and export to overseas of R Bio, Nature Cell’s domestic manufactured stem cell therapy become possible

Biostar Stem Cell Research Institute, joint operated by Nature Cell and R Bio, announced on the 5^th that the composition that increases safety of stem cell storage (application no.: 10-2015-0142806), which Dr. Jeong-Chan Ra has invented, has been decided to be registered for national patent.

This patent includes a technology to extend the time period of storing serum-including-stem cells in cold by over 7 days. Previous technology only allowed three days of storage, which made it impossible for the stem cells manufactured in Korea to be shipped to patients oversea.

Biostar SCRI is planning on applying the technology on regenerative medical treatments made in Korea and supplied to hospitals in Japan, starting March. Also, once approval is gained from the FDA in April, the technology will be applied on Jointstem Clinical trial II and clinical treatments will be manufactured in Korea and injected to patients in the states.

The director of Stem Cell Research Institute, Jeong-Chan Ra, said, “I’m very pleased to bear fruit after returning to the lab, and I thank God for preparing the jewel of our lives”